CBER “Best Practices” Must Be Preserved In Reorg, Mass Bio Tells McClellan
Executive Summary
The Center for Biologics Evaluation & Research ad review team should be transferred to the drug center as part of FDA's reorganization plan, the Massachusetts Biotech Council told Commissioner McClellan
You may also be interested in...
“Project BioShield” Offers Funding Source For Biotech, McClellan Tells BIO
The biotechnology industry should embrace Project BioShield as a guaranteed market for innovative counter-terrorism technologies, Commissioner McClellan said during the Biotechnology Industry Organization CEO and investor conference Feb. 27 in New York
“Project BioShield” Offers Funding Source For Biotech, McClellan Tells BIO
The biotechnology industry should embrace Project BioShield as a guaranteed market for innovative counter-terrorism technologies, Commissioner McClellan said during the Biotechnology Industry Organization CEO and investor conference Feb. 27 in New York
Commissioner McClellan Visits Mass Bio: Phase IV, Orphan Drugs On Agenda
Phase IV commitments should be discussed earlier in the review process to improve the cost-effectiveness of drug development, the Massachusetts Biotechnology Council told FDA Commissioner McClellan